Real-world hepatitis B antiviral treatment trends and adherence to practice guidelines: a large cohort study

References

• Lok ASF, Mcmahon BJ, Brown RS, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63(1):284–306.
   PubMed Web of Science ®Google Scholar
• WHO. Executive summary - global hepatitis report, 2017. World Heal Organ. 2017. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.
   Google Scholar
• WHO. WHO. Global Hepatitis Report. 2017. Available: https://www.Who.Int/En/News-Room/Fact-Sheets/Detail/Hepatitis-c. Cited 2019.; 2017 Mar 24. http://www.who.int/hepatitis.
   Google Scholar
• Michaiel R, Margalit RC, Shteyer E, et al. [Vertical HBV transmission in Jerusalem in the vaccine era]. Harefuah. 2012;151(12):671–674, 722, 721.
   PubMedGoogle Scholar
• Bar‐Shany S, Green MS, Slepon R, et al. Ethnic differences in the prevalence of anti‐hepatitis C antibodies and hepatitis B surface antigen in Israeli blood donors by age, sex, country of birth and origin. J Viral Hepat. 1995;2(3):139–144.
   PubMed Web of Science ®Google Scholar
• Colagrossi L, Hermans LE, Salpini R, et al. Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe. BMC Infect Dis. 2018;18(1). DOI:10.1186/s12879-018-3161-2
   PubMedGoogle Scholar
• Ben-Ari Z, Ashur Y, Daudi N, et al. Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation. Clin Transplant. 2004;18(4):415–422.
   PubMed Web of Science ®Google Scholar
• Shirazi R, Ram D, Rakovsky A, et al. Characterization of hepatitis B and delta coinfection in Israel. BMC Infect Dis. 2018;18(1):4–11.
   PubMedGoogle Scholar
• World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Glob Hepat Program Dep HIV/AIDS. 2016;(June):56.
   Google Scholar
• Lampertico P, Agarwal K, Berg T, et al. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599.
   PubMed Web of Science ®Google Scholar
• Tan M, Bhadoria AS, Cui F, et al. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(2):106–119.
   PubMed Web of Science ®Google Scholar
• Kim LH, Nguyen VG, Trinh HN, et al. Low treatment rates in patients meeting guideline criteria in diverse practice settings. Dig Dis Sci. 2014;59(9):2091–2099.
   PubMed Web of Science ®Google Scholar
• Jung CW, Tan J, Tan N, et al. Evidence for the insufficient evaluation and undertreatment of chronic hepatitis B infection in a predominantly low-income and immigrant population. J Gastroenterol Hepatol. 2010;25(2):369–375.
   PubMed Web of Science ®Google Scholar
• Nguyen VH, Le AK, Trinh HN, et al. Poor adherence to guidelines for treatment of chronic hepatitis B virus infection at primary care and referral practices. Clin Gastroenterol Hepatol. 2019;17(5):957–967.e7.
   PubMed Web of Science ®Google Scholar
• Ogawa E, Yeo YH, Dang N, et al. Diagnosis Rates of Chronic Hepatitis B in Privately Insured Patients in the United States. JAMA Network Open. 2020;3(4):1–10.
   Web of Science ®Google Scholar
• Wright TL. Clinical trial results and treatment resistance with lamivudine in hepatitis B. Semin Liver Dis. 2004;24(SUPPL. 1):31–36.
   PubMedGoogle Scholar
• Eun JR, Lee HJ, Kim TN, et al. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol. 2010;53(1):118–125.
   PubMed Web of Science ®Google Scholar
• Lim YS, Han S, Heo NY, et al. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology. 2014;147(1):152–161.
   PubMed Web of Science ®Google Scholar
• Choi J, Kim HJ, Lee J, et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol. 2019;5(1):30–36.
   PubMed Web of Science ®Google Scholar
• Rizzetto M, Hamid S, Negro F. The changing scenario of hepatitis D. J Hepatol. 2021;74(1):1–12.
   PubMedGoogle Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
   PubMed Web of Science ®Google Scholar
• Shepherd R, Cheung AS, Pang K, et al. Sexual dimorphism in innate immunity: the role of sex hormones and epigenetics. Front Immunol. 2021;11(January):1–16.
   Google Scholar
• Ruggieri A, Gagliardi MC, Anticoli S. Sex-dependent outcome of hepatitis B and C viruses infections: synergy of sex hormones and immune responses?. Front Immunol . 2018;9:2302.
   PubMed Web of Science ®Google Scholar
• Wang SH, Chen PJ, Yeh SH. Gender disparity in chronic hepatitis B: mechanisms of sex hormones. J Gastroenterol Hepatol. 2015;30(8):1237–1245.
   PubMed Web of Science ®Google Scholar